ClinicalTrials.gg
Active, not recruitingNCT06806592Updated Nov 12, 2026

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

A Phase 3 interventional study of Nerandomilast and Placebo matching nerandomilast in Interstitial Lung Diseases and Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases, sponsored by Boehringer Ingelheim. Active, not recruiting at 153 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Now Active, not recruitingPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
414
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim — 4 open to participants now, 6 under way, 4 of them phase 3. Lung Diseases, Interstitial · Boehringer Ingelheim.

Enrollment
6th of 12
414 · median 248
Started
2025
with 2 others
Phase 3
11 of 24
3 open now
Registered
20th of 24
by date

Among the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 in phase 3, and was the 20th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

4 of the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.

Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet 2 times a day for at least 26 weeks and up to 1 year. Participants continue immunosuppressant treatment for their underlying rheumatic disease.

Participants are in the study for about 7.5 to 13 months depending on when they join the study. During this time, they visit the study site about 9 to 10 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Interstitial Lung Diseases
  • Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has systemic rheumatic diseases associated interstitial lung diseases (SARD-ILD), defined as

    • Diagnosis by a rheumatologist (or equally qualified medical physician) with at least 1 of the following SARDs: Rheumatoid arthritis (RA), systemic sclerosis (SSc) (participants must be anticentromere auto-antibody negative), idiopathic inflammatory myopathy (IIM), Sjögren's disease, or mixed connective tissue disease (MCTD) (participants must be anti-U1-ribonucleoprotein particle (RNP) auto-antibody positive)
    • Presence of fibrotic interstitial lung disease (ILD) on high-resolution computed tomography (HRCT), defined as presence of reticular abnormality with traction bronchiectasis with or without honeycombing (HC), with disease extent >10% on HRCT performed within 12 months of Visit 1 or, if historical scan is not available, on baseline HRCT taken prior to Visit 2, as confirmed by central review
  • No lung function improvement and no ILD improvement as a treatment response to (IS) therapy according to both criteria:

    • No improvement in absolute forced vital capacity (FVC) % predicted >5% within the 15 months prior to Visit 1, as measured by 2 spirometry assessments that must be ≥3 months apart. (Note: 1: In the case of multiple PFTs over the 15 months prior to screening, exceptional values of absolute change in FVC % predicted >5% are acceptable if the overall trend of FVC % predicted is declining or stable; note 2: Visit 1 spirometry may be used to fulfill the inclusion criterion if there is only 1 spirometry reading in the 15 months prior to Visit 1)
    • No clinically significant improvement in ILD based on clinician's judgement (including symptoms, imaging/HRCT, or other assessments as considered relevant and documented by the Investigator)
  • FVC ≥45% of predicted normal at Visit 1
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥25% of predicted normal corrected for (Hb) within 3 months prior to or at Visit 1
  • Participants must be on stable treatment with any IS agent for ≥6 months (or ≥3 months for participants with IIM-ILD) prior to visit 2, with the following specifications:

    • If using prednisone, participants must be on stable dose for ≥4 weeks prior to Visit 2
    • If using rituximab, participants must have completed their first cycle >6 months prior to Visit 2
  • If using nintedanib, participants must be on a stable dose for ≥12 weeks prior to Visit 2
  • In the opinion of the Investigator, no change in background standard of care (SoC) treatment with immunosuppressant (IS), immunomodulator (IM), or nintedanib is planned
  • Further inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Organising pneumonia as predominant pattern in the HRCT
  • Prebronchodilator (FEV1)/ forced vital capacity (FVC) \<0.7 at Visit 1
  • Acute ILD exacerbation within 3 months prior to Visit 1 and/or during the screening period, based on Investigator judgement
  • Active vasculitis, unstable or uncontrolled within 8 weeks prior to Visit 1 or during the screening period
  • Any suicidal behaviour in the past 2 years
  • Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the past 3 months or at Visit 1, and/or at Visit 2
  • Use of any of the following medications: cyclophosphamide within 6 months of Visit 1, pirfenidone within 8 weeks of Visit 1
  • Further exclusion criteria apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
414 participants (actual)

Study arms

  • Experimental
    Nerandomilast

    Participants with SARD-ILDs will receive nerandomilast.

    Drug: Nerandomilast

  • Placebo comparator
    Placebo

    Participants with SARD-ILDs will receive placebo.

    Drug: Placebo matching nerandomilast

Interventions

  • Nerandomilast

    Also known as: JASCAYD®

  • DrugPlacebo matching nerandomilast

    Placebo matching nerandomilast

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in quantitative interstitial lung disease (QILD) score [%] on high-resolution computed tomography (HRCT) at Week 26

    QILD will be assessed via quantitative high-resolution computed tomography (qHRCT). QILD are quantitative measures of different radiological patterns associated with lung fibrosis. QLF is a measure of reticulation with architectural distortion. QGGO is a measure of ground glass opacities (i.e. hazy or cloudy areas) within the lung. QHC is a measure of HC within the lung. QILD is the sum of QLF, QGGO, and QHC. Quantification of HRCT scans will be performed centrally via a machine learning algorithm. QILD \[%\] is the QILD volume \[mL\] as a percent of the total lung volume. A higher QILD percentage or volume indicates a higher extent of disease.

    Time frame: At baseline and at Week 26

Secondary outcomes

  1. Absolute change from baseline in quantitative lung fibrosis (QLF) score [%] on HRCT at Week 26

    QLF will be assessed via qHRCT. QLF are quantitative measures of different radiological patterns associated with lung fibrosis. QLF is a measure of reticulation with architectural distortion. Quantification of HRCT scans will be performed centrally via a machine learning algorithm. QILD \[%\] is the QILD volume \[mL\] as a percent of the total lung volume. A higher QILD percentage or volume indicates a higher extent of disease.

    Time frame: At baseline and at Week 26

  2. Absolute change from baseline in quantitative ground glass opacity (QGGO) score [%] on HRCT at Week 26

    QGGO will be assessed via qHRCT. QGGO are quantitative measures of different radiological patterns associated with lung fibrosis. QGGO is a measure of ground glass opacities (i.e. hazy or cloudy areas) within the lung. Quantification of HRCT scans will be performed centrally via a machine learning algorithm. A higher QGGO percentage or volume indicates a higher extent of disease.

    Time frame: At baseline and at Week 26

  3. Absolute change from baseline in vascular volume [%] on HRCT at Week 26

    Time frame: At baseline and at Week 26

  4. Absolute change from baseline in forced vital capacity (FVC) [mL] at Week 26

    FVC will be assessed using standardised spirometry equipment which will be provided centrally with supplies of precalibrated disposable flow sensors. Spirometry will be conducted with the participant in a seated position. It is preferable that the same trained individual (i.e. PFT specialist or pulmonologist) performs the PFTs for a given participant. The best of 3 efforts will be defined as the highest FVC obtained on any of three blows meeting the 2019 American Thoracic Society/European Respiratory Society (ATS/ERS) criteria (with a maximum of eight attempts). Predicted normal values will be calculated according to global lung function initiative (GLI).

    Time frame: At baseline and at Week 26

  5. Absolute change from baseline in supplemental oxygen use over the whole trial for oxygen users at baseline

    Time frame: At baseline and at Week 52

  6. Time to first supplemental oxygen use during the trial for oxygen non-users at baseline

    Time frame: Up to Week 52

  7. Occurrence of infection-related adverse events (AEs) from baseline over the duration of the trial

    Time frame: Up to 1 year

07

Study locations

153 sites

Showing the first 100 of 153 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "time frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a "Document Sharing Agreement". For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Apr 2027, 19 months after the start.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's planned 19 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jul 2027 → Apr 2027 and completion Jul 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 4, 2025
StartActual
Sep 13, 2025
Primary completionEst.
Apr 15, 2027was Jul 2027
CompletionEst.
Apr 28, 2027was Jul 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (2 Spain, 1 China, 1 United States)
  • Sichuan Provincial People's Hospital · Chengdu, China
  • New York Presbyterian Hospital -Columbia University · New York, United States
  • Hospital Universitario Juan Ramón Jimenez · Huelva, Spain
  • Hospital Universitario Virgen del Rocio · Seville, Spain
Show 4 removed
  • People's Hospital of Sichuan Province · Chengdu, China
  • Columbia University Medical Center-New York Presbyterian Hospital · New York, United States
  • Hospital Juan Ramón Jimenez · Huelva, Spain
  • Hospital Virgen del Rocio · Seville, Spain
across 3 updates, Oct 2, 2026 – Nov 12, 2026
Primary completion
Jul 17, 2027→Apr 15, 2027
Oct 14, 2026
Study completion
Jul 30, 2027→Apr 28, 2027
Oct 14, 2026
Enrollment
400 (estimated)→414
Oct 14, 2026
Title
A Study to Test Whether Nerandomilast Helps People With LungfibrosisLung Fibrosis Related to Rheumatic Diseases
Oct 2, 2026
Show all 4 updates
  1. Nov 12, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Spain)
    • Hospital Universitario Juan Ramón Jimenez · Huelva, Spain
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    Show 2 removed
    • Hospital Juan Ramón Jimenez · Huelva, Spain
    • Hospital Virgen del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Oct 28, 2026
    1 site added, 1 site removed
    Show site
    • New York Presbyterian Hospital -Columbia University · New York, United States
    Show 1 removed
    • Columbia University Medical Center-New York Presbyterian Hospital · New York, United States
    + 1 other change: identifiers
  3. Oct 14, 2026
    Primary completion Jul 17, 2027→Apr 15, 2027
    Study completion Jul 30, 2027→Apr 28, 2027
    Enrollment 413→414
    + 1 other change: verification date
  4. Oct 2, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Sichuan Provincial People's Hospital · Chengdu, China
    Show 1 removed
    • People's Hospital of Sichuan Province · Chengdu, China
    Enrollment 400 (estimated)→413 (actual)
    Title A Study to Test Whether Nerandomilast Helps People With LungfibrosisLung Fibrosis Related to Rheumatic Diseases
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06806592
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Sep 13, 2025
Primary completion
Apr 15, 2027 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion